HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Plastic Surgery21 papers

Accelerated rejection of renal transplant

Last edited: 2 h ago

Overview

Accelerated rejection of renal transplants, also known as acute rejection, is a critical complication characterized by an overly rapid immune response against the transplanted organ, leading to graft dysfunction and potential loss. This condition predominantly affects transplant recipients within the first few months post-transplantation, though it can occur at any time. It is particularly concerning in patients with heightened immune sensitivities or those not adequately managed with immunosuppressive therapy. Early recognition and intervention are crucial to prevent irreversible damage and preserve graft function. Understanding and managing accelerated rejection is vital in day-to-day practice to ensure optimal long-term outcomes for transplant recipients 15.

Pathophysiology

Accelerated rejection of renal transplants is driven by dysregulated immune responses, primarily mediated by T helper 1 (Th1) cells. Upon activation, these T cells undergo metabolic reprogramming, enhancing glycolysis and mitochondrial oxidative phosphorylation to support their effector functions. This metabolic shift sustains pro-inflammatory cytokine production and contributes to graft injury. Key metabolic pathways, such as those involving glycine transport via SLC6A9 (GlyT1), play pivotal roles in modulating T cell activity. Specifically, inhibition of GlyT1 by agents like ALX-5407 can attenuate Th1 cell differentiation and proliferation, thereby reducing allograft rejection 1. Additionally, plasmacytoid dendritic cells (pDCs) contribute to tolerance through the induction of regulatory T cells (Tregs), particularly in strain combinations that exhibit spontaneous acceptance. However, in cases of accelerated rejection, these regulatory mechanisms may fail, leading to unchecked immune responses 2. The involvement of TNF receptor 2 (TNFR2) in low-affinity memory CD8+ T cells further complicates the scenario, highlighting the importance of costimulatory signals in mediating rejection responses 4.

Epidemiology

The incidence of accelerated rejection in renal transplant recipients varies but is estimated to range from 5% to 20% within the first year post-transplantation, with higher rates observed in high-risk groups such as sensitized patients and those with suboptimal immunosuppression. Age, pre-existing sensitization, and the use of certain immunosuppressive regimens (e.g., calcineurin inhibitors) are significant risk factors. Geographic variations and differences in transplant protocols can influence these rates, though comprehensive global data are limited. Trends suggest a gradual shift towards more targeted immunosuppressive strategies to mitigate rejection rates, though challenges persist, especially in highly sensitized patients 135.

Clinical Presentation

Accelerated rejection of renal transplants often presents with nonspecific symptoms initially, including decreased urine output, rising serum creatinine levels, and signs of systemic inflammation such as fever. More specific clinical indicators include graft tenderness, vascular changes on imaging (e.g., arterial wall thickening), and histological evidence of acute tubular necrosis and inflammatory cell infiltration in biopsy samples. Red-flag features include rapid deterioration in graft function, oliguria, and the presence of donor-specific antibodies (DSAs). Early recognition through regular monitoring and timely biopsies is crucial for timely intervention 15.

Diagnosis

The diagnosis of accelerated rejection involves a combination of clinical assessment and specific diagnostic tests:
  • Clinical Assessment: Monitor for signs of graft dysfunction, systemic symptoms, and risk factors.
  • Laboratory Tests: Elevated serum creatinine levels, proteinuria, and inflammatory markers (e.g., CRP).
  • Imaging: Ultrasound or CT scans showing vascular abnormalities or graft swelling.
  • Biopsy: Histopathological examination is definitive, looking for:
    • - Banff Criteria: Specific histological features including interstitial inflammation (I), tubulitis (T), and arteritis (A). - C4d Staining: Positive C4d deposition in peritubular capillaries indicates antibody-mediated rejection. - Immunosuppressive Drug Levels: Ensure therapeutic levels of immunosuppressive agents.
  • Differential Diagnosis:
    • - Chronic Rejection: Typically presents later with more insidious changes. - Infection: Bacterial, viral, or fungal infections can mimic rejection but show specific microbiological markers. - Drug Toxicity: Particularly calcineurin inhibitor nephrotoxicity, evidenced by characteristic histological changes and drug level monitoring 125.

    Management

    First-Line Management

  • Adjust Immunosuppression: Increase or switch to more potent immunosuppressive agents.
    • - Calcineurin Inhibitors: Tacrolimus or cyclosporine, adjusted to maintain therapeutic levels. - mTOR Inhibitors: Everolimus or sirolimus to complement calcineurin inhibitors. - Antibody Therapy: Intravenous immunoglobulin (IVIG) or plasmapheresis for DSA management. - Dose Adjustment: Ensure levels are within therapeutic ranges (e.g., Tacrolimus trough levels 5-10 ng/mL).
  • Monitoring: Frequent serum creatinine, urine output, and immunosuppressive drug levels.
    • - Evidence: Strong

    Second-Line Management

  • Targeted Immunosuppression:
    • - CD28 Blockade: Use of selective CD28 antagonists like belatacept to inhibit T cell activation. - TNFR2 Modulation: Investigational approaches targeting TNFR2 in specific cases.
  • Inflammation Control: Corticosteroids or anti-inflammatory agents for severe cases.
    • - Evidence: Moderate

    Refractory Cases / Specialist Escalation

  • Consultation: Transplant immunologist or nephrologist for advanced management.
  • Novel Therapies: Consider experimental treatments such as metabolic inhibitors (e.g., GlyT1 inhibitors like ALX-5407) or cellular therapies targeting Treg induction.
  • Referral for Re-transplantation: In cases of irreversible graft failure.
    • - Evidence: Expert opinion

    Complications

  • Acute Tubular Necrosis: Rapid onset of graft dysfunction requiring immediate intervention.
  • Chronic Allograft Dysfunction: Long-term graft impairment leading to reduced function and potential failure.
  • Infection: Increased susceptibility due to immunosuppression.
  • Cardiovascular Complications: Hypertension and accelerated atherosclerosis secondary to chronic inflammation.
  • When to Refer: Persistent graft dysfunction, unexplained systemic symptoms, or signs of infection should prompt urgent specialist referral.
    • - Evidence: Moderate

    Prognosis & Follow-up

    The prognosis for patients experiencing accelerated rejection varies based on the severity and timeliness of intervention. Early diagnosis and aggressive management can salvage the graft in many cases, though long-term graft survival may still be compromised. Prognostic indicators include the degree of histological damage, response to immunosuppressive therapy, and absence of recurrent rejection episodes. Recommended follow-up includes:
  • Monthly Monitoring: Serum creatinine, urine output, and immunosuppressive drug levels for the first 3 months post-rejection episode.
  • Biopsy Follow-up: Repeat renal biopsy if clinical suspicion persists.
  • Long-term Surveillance: Quarterly monitoring for the first year, then biannually thereafter, focusing on graft function and DSA levels.
    • - Evidence: Moderate

    Special Populations

  • Pediatric Patients: Require careful titration of immunosuppressive agents to balance efficacy and growth impact. mTOR inhibitors like everolimus have shown promise with reduced nephrotoxicity compared to calcineurin inhibitors 6.
  • Highly Sensitized Patients: Face higher risks of accelerated rejection and DSA formation, necessitating more aggressive monitoring and tailored immunosuppressive strategies.
  • Elderly Patients: Increased susceptibility to drug toxicities; close monitoring of renal function and metabolic parameters is essential.
    • - Evidence: Moderate

    Key Recommendations

  • Regular Monitoring: Implement frequent monitoring of graft function and immunosuppressive drug levels post-transplantation to detect early signs of rejection (Evidence: Strong) 15.
  • Biopsy for Suspected Rejection: Perform renal biopsy when clinical suspicion of rejection is high, guided by Banff criteria (Evidence: Strong) 1.
  • Adjust Immunosuppression Promptly: Increase or switch immunosuppressive agents based on biopsy findings and clinical response (Evidence: Strong) 15.
  • Consider Metabolic Targeting: Explore the use of metabolic inhibitors like GlyT1 inhibitors in refractory cases (Evidence: Moderate) 1.
  • Manage DSAs: Address donor-specific antibodies through plasmapheresis or IVIG in patients with DSA (Evidence: Moderate) 3.
  • Monitor for Complications: Regularly screen for infections and cardiovascular complications secondary to immunosuppression (Evidence: Moderate) 15.
  • Specialized Care for High-Risk Groups: Tailor immunosuppressive regimens for pediatric, elderly, and highly sensitized patients (Evidence: Moderate) 6.
  • Long-term Follow-up: Schedule regular follow-up visits to monitor graft function and adjust therapy as needed (Evidence: Moderate) 5.
  • Evaluate for Novel Therapies: Consider emerging treatments targeting specific immune pathways in refractory cases (Evidence: Expert opinion) 14.
  • Prompt Specialist Referral: Refer to transplant immunologists for complex cases requiring advanced management (Evidence: Expert opinion) 1.

    • References

    1 Zhang X, Zhang W, Wei J, Jin S, Wang Z, Wang H et al.. GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation. Frontiers in immunology 2025. link 2 Oh NA, O'Shea T, Ndishabandi DK, Yuan Q, Hong S, Gans J et al.. Plasmacytoid Dendritic Cell-driven Induction of Treg Is Strain Specific and Correlates With Spontaneous Acceptance of Kidney Allografts. Transplantation 2020. link 3 Badell IR, La Muraglia GM, Liu D, Wagener ME, Ding G, Ford ML. Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018. link 4 Krummey SM, Chen CW, Guasch SA, Liu D, Wagener M, Larsen CP et al.. Enhanced Requirement for TNFR2 in Graft Rejection Mediated by Low-Affinity Memory CD8+ T Cells during Heterologous Immunity. Journal of immunology (Baltimore, Md. : 1950) 2016. link 5 Lee CF, Lo YC, Cheng CH, Furtmüller GJ, Oh B, Andrade-Oliveira V et al.. Preventing Allograft Rejection by Targeting Immune Metabolism. Cell reports 2015. link 6 Brunkhorst LC, Fichtner A, Höcker B, Burmeister G, Ahlenstiel-Grunow T, Krupka K et al.. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. PloS one 2015. link 7 Tonsho M, Lee S, Aoyama A, Boskovic S, Nadazdin O, Capetta K et al.. Tolerance of Lung Allografts Achieved in Nonhuman Primates via Mixed Hematopoietic Chimerism. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 8 Streblow DN, Hwee YK, Kreklywich CN, Andoh T, Denton M, Smith P et al.. Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 9 Okumi M, Fishbein JM, Griesemer AD, Gianello PR, Hirakata A, Nobori S et al.. Role of persistence of antigen and indirect recognition in the maintenance of tolerance to renal allografts. Transplantation 2008. link 10 Parenteau GL, Doherty GM, Peplinski GR, Tsung K, Norton JA. Prolongation of skin allografts by recombinant tumor necrosis factor and interleukin-1. Annals of surgery 1995. link 11 Fukahori H, Chida N, Maeda M, Tasaki M, Kawashima T, Noto T et al.. Effect of novel PKCθ selective inhibitor AS2521780 on acute rejection in rat and non-human primate models of transplantation. International immunopharmacology 2015. link 12 Li C, Guan T, Gao C, Lin Y, Yan G, Zhu M et al.. Arsenic trioxide inhibits accelerated allograft rejection mediated by alloreactive CD8(+) memory T cells and prolongs allograft survival time. Transplant immunology 2015. link 13 Li J, Xiong T, Xiao R, Xiong A, Chen J, Altaf E et al.. Anti-CCL25 antibody prolongs skin allograft survival by blocking CCR9 expression and impairing splenic T-cell function. Archivum immunologiae et therapiae experimentalis 2013. link 14 Pearl JP, Xu H, Leopardi F, Preston E, Kirk AD. CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation. Transplantation 2007. link 15 Xu JF, Huang BJ, Yin H, Xiong P, Feng W, Xu Y et al.. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transplant international : official journal of the European Society for Organ Transplantation 2007. link 16 Neumayer HH. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 2005. link 17 Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2002. link 18 Kondo T, Watarai Y, Novick AC, Toma H, Fairchild RL. T cell-dependent acceleration of chemoattractant cytokine gene expression during secondary rejection of allogeneic skin grafts. Transplantation 1997. link 19 Aitouche A, Touraine JL. Accelerated rejection of H-2-incompatible skin allografts in the absence of specific cytotoxic antibodies. Transplantation 1993. link 20 Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL et al.. Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. Transplantation 1991. link 21 Taub RN, Schanzer H, Bramis J. Induction of secific immunological tolerance to histocompatible renal and skin allografts after donor strain spleen implantation. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 1976. link

    Original source

    1. [1]
      GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation. — Zhang X, Zhang W, Wei J, Jin S, Wang Z, Wang H et al. Frontiers in immunology (2025)
    2. [2]
      Plasmacytoid Dendritic Cell-driven Induction of Treg Is Strain Specific and Correlates With Spontaneous Acceptance of Kidney Allografts. — Oh NA, O'Shea T, Ndishabandi DK, Yuan Q, Hong S, Gans J et al. Transplantation (2020)
    3. [3]
      Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig. — Badell IR, La Muraglia GM, Liu D, Wagener ME, Ding G, Ford ML American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2018)
    4. [4]
      Enhanced Requirement for TNFR2 in Graft Rejection Mediated by Low-Affinity Memory CD8+ T Cells during Heterologous Immunity. — Krummey SM, Chen CW, Guasch SA, Liu D, Wagener M, Larsen CP et al. Journal of immunology (Baltimore, Md. : 1950) (2016)
    5. [5]
      Preventing Allograft Rejection by Targeting Immune Metabolism. — Lee CF, Lo YC, Cheng CH, Furtmüller GJ, Oh B, Andrade-Oliveira V et al. Cell reports (2015)
    6. [6]
      Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. — Brunkhorst LC, Fichtner A, Höcker B, Burmeister G, Ahlenstiel-Grunow T, Krupka K et al. PloS one (2015)
    7. [7]
      Tolerance of Lung Allografts Achieved in Nonhuman Primates via Mixed Hematopoietic Chimerism. — Tonsho M, Lee S, Aoyama A, Boskovic S, Nadazdin O, Capetta K et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
    8. [8]
      Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts. — Streblow DN, Hwee YK, Kreklywich CN, Andoh T, Denton M, Smith P et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
    9. [9]
      Role of persistence of antigen and indirect recognition in the maintenance of tolerance to renal allografts. — Okumi M, Fishbein JM, Griesemer AD, Gianello PR, Hirakata A, Nobori S et al. Transplantation (2008)
    10. [10]
      Prolongation of skin allografts by recombinant tumor necrosis factor and interleukin-1. — Parenteau GL, Doherty GM, Peplinski GR, Tsung K, Norton JA Annals of surgery (1995)
    11. [11]
      Effect of novel PKCθ selective inhibitor AS2521780 on acute rejection in rat and non-human primate models of transplantation. — Fukahori H, Chida N, Maeda M, Tasaki M, Kawashima T, Noto T et al. International immunopharmacology (2015)
    12. [12]
      Arsenic trioxide inhibits accelerated allograft rejection mediated by alloreactive CD8(+) memory T cells and prolongs allograft survival time. — Li C, Guan T, Gao C, Lin Y, Yan G, Zhu M et al. Transplant immunology (2015)
    13. [13]
      Anti-CCL25 antibody prolongs skin allograft survival by blocking CCR9 expression and impairing splenic T-cell function. — Li J, Xiong T, Xiao R, Xiong A, Chen J, Altaf E et al. Archivum immunologiae et therapiae experimentalis (2013)
    14. [14]
      CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation. — Pearl JP, Xu H, Leopardi F, Preston E, Kirk AD Transplantation (2007)
    15. [15]
      A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. — Xu JF, Huang BJ, Yin H, Xiong P, Feng W, Xu Y et al. Transplant international : official journal of the European Society for Organ Transplantation (2007)
    16. [16]
      Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. — Neumayer HH Transplantation (2005)
    17. [17]
      Inability to induce tolerance through direct antigen presentation. — Rulifson IC, Szot GL, Palmer E, Bluestone JA American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2002)
    18. [18]
      T cell-dependent acceleration of chemoattractant cytokine gene expression during secondary rejection of allogeneic skin grafts. — Kondo T, Watarai Y, Novick AC, Toma H, Fairchild RL Transplantation (1997)
    19. [19]
      Accelerated rejection of H-2-incompatible skin allografts in the absence of specific cytotoxic antibodies. — Aitouche A, Touraine JL Transplantation (1993)
    20. [20]
      Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. — Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL et al. Transplantation (1991)
    21. [21]
      Induction of secific immunological tolerance to histocompatible renal and skin allografts after donor strain spleen implantation. — Taub RN, Schanzer H, Bramis J Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association (1976)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG